Last Updated on December 31, 2023 by The Health Master
Punjab: Panacea Biotec has recently announced that its material wholly-owned subsidiary, Panacea Biotec Pharma Limited (“PBPL”) has received eight observations from United States Food and Drug Administration (USFDA) at the end of the inspection.
The inspection was held at Panacea Biotec Pharma Limited’s facility at Baddi, Himachal Pradesh, India between May 30, 2022 and June 08, 2022.
PBPL was issued a ‘USFDA Form 483‘ with eight (8) observations, which are related to improvements in existing procedures and are addressable,” the company stated.
USFDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator (s) has observed any conditions that, in their judgment, may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts.
“PBPL will respond to the USFDA within the stipulated time period and work closely with USFDA to close the said observations and the closure of Warning Letter issued by the US FDA earlier on September 24, 2020,” the company added in a BSE filing.
“We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards,” Panacea further added.
USFDA gives 5 observations to Glenmark Pharma for Goa facility
USFDA gives 10 observations to Sun Pharm
USFDA gives Zero Observations to SMS Lifesciences
USFDA issues 4 Observations to Lupin for Tarapur Facility
USFDA gives 13 observations to Lupin
USFDA complete audit of Granules Pharmaceuticals with 3 observations
Why has aspirin advice for heart protection changed?
USFDA gives tentative nod to Alembic Pharma for Dasatinib tablets
CDSCO classifies 214 Medical Devices under Medical Devices Rule, 2017
PCI: Pharmacy Council of India is against e-selling of medicines
USFDA gives final approval for Adapalene and Benzoyl Peroxide Topical Gel
FDA Haryana and police raid, consignment of medicines recovered
Drug recall: 2.1 million doses of medicine recalled due to this reason
Rs 1050 per unit for Whole Blood, SBTC has fixed the maximum prices of Blood and its components
USFDA gives approval for Leuprolide Acetate Injection
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
